Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
The DOI matches its Crossref record.
Abstract
This analysis aims to describe the outcomes of two nonambulatory patients with Duchenne muscular dystrophy (DMD) who participated in two clinical studies. The two consecutive trials of eteplirsen (studies 201 and 202) were conducted in patients with DMD (N = 12) and confirmed genetic mutations amenable to exon 51 skipping. In study 201, 12 patients were randomized to receive once-weekly, double-blind intravenous infusions of eteplirsen 30 or 50 mg/kg or placebo for 24 weeks; patients then received open-label eteplirsen during weeks 25 through 28. All 12 patients continued onto open-label extension study 202 and received long-term treatment with eteplirsen. We compared cardiac, pulmonary, and upper limb function and dystrophin production in the nonambulatory twin patients versus the 10 ambulatory patients through 240 combined treatment weeks. Ten study patients remained ambulatory through both studies, while the identical twin patients both experienced early, rapid loss of ambulation. The twin patients had greater disease severity at baseline (6-minute walk test [6MWT], 330 and 256 m) versus the other patients (n = 10; 6MWT range, 341–418 m). They maintained cardiac and upper limb function through combined week 240, with outcomes similar to those of the patients who remained ambulatory. Dystrophin production was confirmed following eteplirsen treatment. Despite the loss of ambulation, other markers of disease progression remained relatively stable in the eteplirsen-treated twin patients and were similar to those of the ambulatory patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Four uncharged phosphorodiamidate morpholino oligomer (PMO) AONs have been approved by the FDA: Casimersen, which targets exons 45 (Shirley, 2021); Eteplirsen, which targets exon 51 (Mendell et al., 2016; Alfano et al., 2019); and Viltolarsen (Roshmi and Yokota, 2019) and Golodirsen (Frank et al., 2020), which target exon 53.”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Alfano et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 29
- Kole, 2015, Exon skipping therapy for Duchenne muscular dystrophy, Adv Drug Deliv Rev, 87, 104, 10.1016/j.addr.2015.05.008 · DOI · Paper page
- Mendell, 2013, Eteplirsen for the treatment of Duchenne muscular dystrophy, Ann Neurol, 74, 637, 10.1002/ana.23982 · DOI · Paper page
- McNeil, 2010, Duchenne muscular dystrophy: drug development and regulatory considerations, Muscle Nerve, 41, 740, 10.1002/mus.21623 · DOI
- Bushby, 2010, Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care, Lancet Neurol, 9, 177, 10.1016/S1474-4422(09)70272-8 · DOI · Paper page
- Bushby, 2010, Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management, Lancet Neurol, 9, 77, 10.1016/S1474-4422(09)70271-6 · DOI · Paper page
- Fayssoil, 2010, Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics, Heart Fail Rev, 15, 103, 10.1007/s10741-009-9156-8 · DOI
- Voit, 2014, Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study, Lancet Neurol, 13, 987, 10.1016/S1474-4422(14)70195-4 · DOI · Paper page
- Bushby, 2014, Ataluren treatment of patients with nonsense mutation dystrophinopathy, Muscle Nerve, 50, 477, 10.1002/mus.24332 · DOI · Paper page
- Mendell, 2016, Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy, Ann Neurol, 79, 257, 10.1002/ana.24555 · DOI · Paper page
- Charleston, 2018, Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production, Neurology, 90, e2146, 10.1212/WNL.0000000000005680 · DOI · Paper page
- Poole, 2005, Measuring dexterity in children using the Nine-hole Peg Test, J Hand Ther, 18, 348, 10.1197/j.jht.2005.04.003 · DOI · Paper page
- Pane, 2014, Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes, PLoS One, 9, e108205, 10.1371/journal.pone.0108205 · DOI
- Mazzone, 2011, Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study, Neurology, 77, 250, 10.1212/WNL.0b013e318225ab2e · DOI · Paper page
- LoMauro, 2015, Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options, Ther Clin Risk Manag, 11, 1475
- Roberto, 2011, The natural history of cardiac and pulmonary function decline in patients with Duchenne muscular dystrophy, Spine, 36, E1009, 10.1097/BRS.0b013e3181fea1ed · doi:10.1097/brs.0b013e3181fea1ed
- Mayer, 2015, Characterization of pulmonary function in Duchenne muscular dystrophy, Pediatr Pulmonol, 50, 487, 10.1002/ppul.23172 · DOI
- Connolly, 2015, Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy, Muscle Nerve, 51, 522, 10.1002/mus.24346 · DOI
- Mayhew, 2007, Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy, Muscle Nerve, 35, 36, 10.1002/mus.20654 · DOI
- Mayer, 2017, Advances in pulmonary care in Duchenne muscular dystrophy, US Neurology, 13, 35
- Finder, 2017, Pulmonary endpoints in Duchenne muscular dystrophy. A workshop summary, Am J Respir Crit Care Med, 196, 512, 10.1164/rccm.201703-0507WS · DOI
- Connolly, 2016, Clinical trial readiness in non-ambulatory boys and men with Duchenne muscular dystrophy: MDA-DMD network follow-up, Muscle Nerve, 54, 681, 10.1002/mus.25089 · doi:10.1002/mus.25089
- Duboc, 2005, Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy, J Am Coll Cardiol, 45, 855, 10.1016/j.jacc.2004.09.078 · DOI
- Tandon, 2015, Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy, J Am Heart Assoc, 4, e001338, 10.1161/JAHA.114.001338 · doi:10.1161/jaha.114.001338
- Schram, 2013, All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy, J Am Coll Cardiol, 61, 948, 10.1016/j.jacc.2012.12.008 · DOI · Paper page
- Birnkrant, 2016, Cardiac phenotype determines survival in Duchenne muscular dystrophy, Pediatr Pulmonol, 51, 70, 10.1002/ppul.23215 · doi:10.1002/ppul.23215
- Ricotti, 2016, Upper limb evaluation in Duchenne muscular dystrophy: fat-water quantification by MRI, muscle force and function define endpoints for clinical trials, PLoS One, 11, e0162542, 10.1371/journal.pone.0162542 · DOI
- Henricson, 2013, The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures, Muscle Nerve, 48, 55, 10.1002/mus.23808 · DOI · Paper page
- Vestergaard, 2001, Fracture risk in patients with muscular dystrophy and spinal muscular atrophy, J Rehabil Med, 33, 150, 10.1080/165019701750300609 · DOI
- Archer, 2016, Duchenne muscular dystrophy: the management of scoliosis, J Spine Surg, 2, 185, 10.21037/jss.2016.08.05 · DOI
Cited by
Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,312
Antisense technology: A review
Crooke, S. T., Liang, X.-H., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 326
Alternative splicing in neurodegenerative disease and the promise of RNA therapies
Nikom, D., & Zheng, S. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00717-6 · Cited by 190
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Alfano, L. N., Charleston, J. S., Connolly, A. M., Cripe, L., Donoghue, C., Dracker, R., Dworzak, J., Eliopoulos, H., Frank, D. E., Lewis, S., Lucas, K., Lynch, J., Milici, A. J., Flynt, A., Naughton, E., Rodino-Klapac, L. R., Sahenk, Z., Schnell, F. J., Young, G. D., Mendell, J. R., & Lowes, L. P.
- Affiliations
- Pediatrics, Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH
- Sarepta Therapeutics, Inc., Cambridge, MA
- Currently: Pediatrics, Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH
- Summerwood Pediatrics/Infusacare Medical Services, PC, Liverpool, NY
- Flagship Biosciences, Westminster, CO
- PharPoint Research, Durham, NC
- Venue
- Medicine
- Published
- 2019-06
- Volume
- 98
- Issue
- 26
- Pages
- e15858
- ISSN
- 0025-7974
- 1536-5964
- Cited by
- 79
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. https://app.cochat.ai/papers/10.1097/md.0000000000015858
- The paper
- Alfano, L. N., Charleston, J. S., Connolly, A. M., Cripe, L., Donoghue, C., Dracker, R., Dworzak, J., Eliopoulos, H., Frank, D. E., Lewis, S., Lucas, K., Lynch, J., Milici, A. J., Flynt, A., Naughton, E., Rodino-Klapac, L. R., Sahenk, Z., Schnell, F. J., Young, G. D., . . . Lowes, L. P. (2019). Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine. https://doi.org/10.1097/md.0000000000015858
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.